New Advances in IAHA Injections for Orthopedic Care
Key Growth Drivers and Opportunities
Growing Demand for Minimally Invasive Treatments: Orthopedic intra-articular hyaluronic acid (IAHA) injection market growth primarily due to the rise in the demand for minimally invasive treatments. The main factor is that individuals are more and more turning to fast, safe, and efficient options that do not interfere with their lifestyle. These patients,' electromechanical effector haptic display (EEHD), 'also benefit from a significantly lower recovery time, a crucial aspect when outpatient surgery is concerned. This is why patients and doctors are attracted to this method of treating because it is not only a one-time, surgical method but also a follow-up procedure in most cases by healthcare professionals.
Challenges
The hyaluronic acid injection field of orthopedics (HA) intra-articular is a limited market. Firstly, in the situation of inconsistent clinical outcomes, not all patients are able to get significant pain relief or improvement in mobility. This is about patients facing the clinical side effects from drugs given by a doctor. Apart from that, the high cost of treatment and the restriction of the purchasing power or the non-reimbursable insurance process will lead to the restraining of the use of the treatment of the patients. The issue of the temporary relief of symptoms will often encourage medication over longer periods, but the need for repetitive injections can serve as a deterrent.
Innovation and Expansion
JOYCLU, A Monthly Intra-Articular Injection for Osteoarthritis Relief, is introduced by Ono and Seikagaku
In May 2021, the joint function improvement drug JOYCLU 30mg Intra-articular Injection (generic name: diclofenac etalhyaluronate sodium; 'JOYCLU') was introduced by Ono Pharmaceutical Co., Ltd. and Seikagaku Corporation. Seikagaku was granted manufacturing and marketing approval in Japan for this product. The intra-articular injection of JOYCLU, which is authorized for the treatment of osteoarthritis (hip and knee joints), is anticipated to alleviate osteoarthritis symptoms once every four weeks.
Hyaluronic acid and the anti-inflammatory medication diclofenac are chemically bound in the JOYCLU formulation by Seikagaku's in-house technology. It is intended to hydrolyze diclofenac in the joint and release it. The intra-articular injection of JOYCLU, which is authorized for the treatment of osteoarthritis (hip and knee joints), is anticipated to alleviate osteoarthritis symptoms once every four weeks.
Inventive Sparks, Expanding Markets
Multiple key players currently conduct business in the orthopedic intra-articular hyaluronic acid (IAHA) injection market, for instance, Anika Therapeutics, Inc., Zimmer Biomet, Ferring, LG Chem, Bioventus LLC, and others. By introducing new products, getting involved in the market, teaming up thereby forming partnerships, and through patient education and reimbursement means which also enhance patient access, IAHA-based injectable companies are in the process of their growth.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.
TIME BUSINESS NEWS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Family secures lawfulness certificate for Pembrokeshire site
A call to retain a leisure use of a parcel of land near the Pembrokeshire seaside, used for more than 50 years, has been given the go-ahead despite local objections. In an application to Pembrokeshire Coast National Park, Phillip Thomas of Rhydlewis, through agent Preseli Planning Ltd, sought a certificate of lawful development for land east of Bryntirion Lodge, Cippyn, St Dogmaels. An application for a certificate of lawfulness allows an applicant to stay at a development if they can provide proof of occupancy over a prolonged period. A supporting statement said the application had been made after the refusal of a partly retrospective application for the siting of a holiday pod on the land. It said: 'The land has been in family ownership for decades and the applicants have witnessed and enjoyed the use of the land for leisure purposes for over 40 years. Originally established by their grandfather, the site has been handed down through the generations. Resolving the matter is therefore a highly sensitive matter for the family.' It added: 'Based on the evidence available, it has been established that the leisure use of the land commenced in the 1970s and the use has existed in some form since this time, as the land has been passed down through three generations of the same family.' It said that part of the site was used to store builders' materials temporarily in circa 2019, but the leisure use had not been abandoned. Read more Pembrokeshire village's football club grounds expansion call Pembrokeshire overnight campervan trial approval expected Call to keep car pod at Pembrokeshire supermarket An officer report said objections had been received locally, contesting the claims made in the application for a Certificate of Lawfulness relating to leisure use, describing it as 'an overgrown, steep, and largely inaccessible tract, with significant areas covered by dense vegetation and invasive species'. Objectors also said they have never witnessed any family activities at the site, saying it was primarily used as a dumping ground for builder's debris, the report added. 'Officers recognise the concerns raised by local residents regarding the use and condition of the site, including issues related to dumping and unauthorised development,' it said, adding: 'However, the statutory test for a Certificate of Lawfulness is whether the use has occurred for the relevant period to render it lawful, not whether the use is desirable or appropriate.' It said, based 'on the totality of evidence submitted' the applicant had 'demonstrated on the balance of probabilities that the use of the land for leisure purposes has been carried out continuously for at least ten years prior to the submission of the application'.
Business Upturn
5 hours ago
- Business Upturn
CDSL shares drop 3% as Q1 net profit falls 23.6% YoY to Rs 102.4 crore, EBITDA down 15.1%
By Aman Shukla Published on July 28, 2025, 09:23 IST Shares of Central Depository Services (India) Ltd (CDSL) declined over 3% in Monday's trade after the company posted a sharp drop in net profit for the June quarter (Q1 FY26). As of 9:21 AM, the shares were trading 2.88% lower at Rs 1,568.20. CDSL reported a 23.6% year-on-year (YoY) decline in net profit at ₹102.4 crore, compared to ₹134 crore in the same period last year. While revenue remained flat, rising marginally by 0.6% to ₹259 crore from ₹257.4 crore, the company's operating performance took a hit. EBITDA came in at ₹130.6 crore, down 15.1% YoY, while EBITDA margin dropped to 50.44% from 60% a year ago, indicating pressure on profitability despite steady top-line growth. CDSL shares traded between ₹1,549.00 and ₹1,580.00 today. The stock opened at ₹1,550.00, slightly lower than its previous close of ₹1,614.70. It remains well above its 52-week low of ₹1,047.45 but below the 52-week high of ₹1,989.80. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Time Business News
a day ago
- Time Business News
New Advances in IAHA Injections for Orthopedic Care
Orthopedic intra-articular hyaluronic acid (IAHA) injection is a treatment where a natural substance found in hyaluronic acid-format fluid is injected into a joint, most commonly to relieve pain, pain, pain and improve mobility in patients with chronic osteoarthritis. The future of orthopedic intra-articular hyaluronic acid (IAHA) injection market looks promising the future, cases of increasing osteoarthritis, the patient's priority for non-surreal treatment, and is inspired by innovations in long-lasting ha formulations. Extending access to emerging markets such as outpatient settings, favorable regulatory support, and Asia-Pacific will further boost demand for increase in demand. Advances such as combination therapy and better distribution methods are also expected to increase the results of treatment and make market access wider. Key Growth Drivers and Opportunities Growing Demand for Minimally Invasive Treatments: Orthopedic intra-articular hyaluronic acid (IAHA) injection market growth primarily due to the rise in the demand for minimally invasive treatments. The main factor is that individuals are more and more turning to fast, safe, and efficient options that do not interfere with their lifestyle. These patients,' electromechanical effector haptic display (EEHD), 'also benefit from a significantly lower recovery time, a crucial aspect when outpatient surgery is concerned. This is why patients and doctors are attracted to this method of treating because it is not only a one-time, surgical method but also a follow-up procedure in most cases by healthcare professionals. Challenges The hyaluronic acid injection field of orthopedics (HA) intra-articular is a limited market. Firstly, in the situation of inconsistent clinical outcomes, not all patients are able to get significant pain relief or improvement in mobility. This is about patients facing the clinical side effects from drugs given by a doctor. Apart from that, the high cost of treatment and the restriction of the purchasing power or the non-reimbursable insurance process will lead to the restraining of the use of the treatment of the patients. The issue of the temporary relief of symptoms will often encourage medication over longer periods, but the need for repetitive injections can serve as a deterrent. Innovation and Expansion JOYCLU, A Monthly Intra-Articular Injection for Osteoarthritis Relief, is introduced by Ono and Seikagaku In May 2021, the joint function improvement drug JOYCLU 30mg Intra-articular Injection (generic name: diclofenac etalhyaluronate sodium; 'JOYCLU') was introduced by Ono Pharmaceutical Co., Ltd. and Seikagaku Corporation. Seikagaku was granted manufacturing and marketing approval in Japan for this product. The intra-articular injection of JOYCLU, which is authorized for the treatment of osteoarthritis (hip and knee joints), is anticipated to alleviate osteoarthritis symptoms once every four weeks. Hyaluronic acid and the anti-inflammatory medication diclofenac are chemically bound in the JOYCLU formulation by Seikagaku's in-house technology. It is intended to hydrolyze diclofenac in the joint and release it. The intra-articular injection of JOYCLU, which is authorized for the treatment of osteoarthritis (hip and knee joints), is anticipated to alleviate osteoarthritis symptoms once every four weeks. Inventive Sparks, Expanding Markets Multiple key players currently conduct business in the orthopedic intra-articular hyaluronic acid (IAHA) injection market, for instance, Anika Therapeutics, Inc., Zimmer Biomet, Ferring, LG Chem, Bioventus LLC, and others. By introducing new products, getting involved in the market, teaming up thereby forming partnerships, and through patient education and reimbursement means which also enhance patient access, IAHA-based injectable companies are in the process of their growth. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
